TNFα rs1800629 Polymorphism and Response to Anti-TNFα Treatment in Behçet Syndrome: Data from an Italian Cohort Study. [PDF]
J Pers Med, 2023 Padula MC +6 more
europepmc +1 more source
Recent Insights into the Management of Behçet Syndrome. [PDF]
J Inflamm Res, 2021 Ozguler Y, Ozdede A, Hatemi G.
europepmc +1 more source
Anti-tubulin-alpha-1c antibody as a marker of value in Behçet syndrome. [PDF]
Clin Rheumatol, 2022 Amin MM, Abdel Latif OM.
europepmc +1 more source
COVID-19 among patients with Behçet syndrome in the United States. [PDF]
Clin Rheumatol, 2022 Pakhchanian H, Raiker R, Kardeş S.
europepmc +1 more source
Exploring the pharmacological and adverse reaction mechanism of a drug by network pharmacology strategy: Using colchicine to treat Behcet syndrome as an example. [PDF]
Medicine (Baltimore), 2023 Li S, Wang L, Wang Y, Zhang C.
europepmc +1 more source
Infliximab versus alpha interferon in the treatment of Behçet’s disease: the BIO BEHÇET’S RCT
Efficacy and Mechanism EvaluationBackground While biologic therapy, typically with infliximab or Roferon, was used for Behçet syndrome after first-line immunosuppressants, no high-quality randomised trials or predictive biomarkers were available.
Robert J Moots +8 more
doaj +1 more source
Effects of anti-SARS-CoV-2 vaccination on safety and disease exacerbation in patients with Behçet syndrome in a monocentric cohort. [PDF]
Int J Rheum Dis, 2022 Apaydin H +9 more
europepmc +1 more source
Haemostatic Parameters in Patients with Behçet’s Disease
Sultan Qaboos University Medical Journal, 2014 Objectives: This study aimed to evaluate the cause of thrombosis in Behçet’s disease (BD) patients, since abnormalities in coagulation and fibrinolytic parameters have shown contradictory results.
Juma K. Alkaabi +3 more
doaj